Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from COMPASS Pathways ( (CMPS) ).
Compass Pathways announced the successful achievement of the primary endpoint in their Phase 3 COMP005 trial, which evaluates the efficacy of COMP360 for treatment-resistant depression. The trial demonstrated a statistically significant reduction in symptom severity with a single dose of COMP360 compared to placebo. The company plans to discuss these findings with the FDA. The ongoing COMP005 trial involves 258 participants and aims to assess the safety and efficacy of a single dose of 25 mg COMP360 versus placebo. The COMP006 trial, running in parallel, compares different doses of COMP360 and is expected to provide additional data in the second half of 2026.
The most recent analyst rating on (CMPS) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.
Spark’s Take on CMPS Stock
According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.
Compass Pathways demonstrates potential due to its strong equity position and progress in clinical trials. However, significant financial risks due to a lack of revenue and increasing operational costs weigh heavily on its performance. The stock’s upward momentum is promising, but valuation remains challenging due to negative profitability. The recent earnings call underscores both strategic progress and financial challenges, which tempers the overall outlook.
To see Spark’s full report on CMPS stock, click here.
More about COMPASS Pathways
Compass Pathways is a company operating in the mental health industry, focusing on developing treatments for difficult-to-treat mental health conditions. Their primary product is COMP360, a synthetic, proprietary formulation of psilocybin, which is under investigation for treatment-resistant depression (TRD).
Average Trading Volume: 1,205,189
Technical Sentiment Signal: Sell
Current Market Cap: $429.9M
For a thorough assessment of CMPS stock, go to TipRanks’ Stock Analysis page.